Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413321 | 1.00 | TAAR1 (0.53) | TAAR1AOC3L3MBTL1CASRALDH1A1 | |
| SCHEMBL17755174 | 0.86 | AOC3 (0.50) | TAAR1AOC3L3MBTL1CASRALDH1A1 | |
| SCHEMBL19291675 | 0.86 | AOC3 (0.50) | TAAR1AOC3L3MBTL1CASRALDH1A1 | |
| SCHEMBL10192231 | 0.83 | CASR (0.51) | TAAR1AOC3L3MBTL1CASRALDH1A1 | |
| SCHEMBL11992976 | 0.83 | CASR (0.51) | TAAR1AOC3L3MBTL1CASRALDH1A1 | |
| SCHEMBL14162717 | 0.83 | CASR (0.51) | TAAR1AOC3L3MBTL1CASRALDH1A1 | |
| SCHEMBL2632814 | 0.83 | CASR (0.51) | TAAR1AOC3L3MBTL1CASRALDH1A1 | |
| SCHEMBL11081355 | 0.83 | AOC3 (0.54) | TAAR1AOC3L3MBTL1CASRALDH1A1 | |
| SCHEMBL7412592 | 0.82 | TAAR1 (0.56) | TAAR1AOC3L3MBTL1CASRALDH1A1 | |
| SCHEMBL11534196 | 0.82 | TAAR1 (0.60) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109219604-B | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2021-09-24 | — | — | CN | disclosed |
| EP-3440067-B1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2021-05-26 | — | — | EP | disclosed |
| EP-3440067-B1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2021-05-26 | — | — | EP | disclosed |
| EP-3440067-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Hoffmann-La Roche AG (CH) | 2019-02-13 | — | — | EP | disclosed |
| CN-109219604-A | Tetrahydroisoquinoline estrogenic agents and application thereof | 豪夫迈·罗氏有限公司 | 2019-01-15 | — | — | CN | disclosed |
| US-9969732-B2 | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969732-B2 | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969732-B2 | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170320871-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320871-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2007047991-A1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047991-A1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| EP-1704161-A1 | HELIX 12 DIRECTED STEROIDAL PHARMACEUTICAL PRODUCTS | Endorecherche, Inc. (CA) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005066194-A1 | HELIX 12 DIRECTED STEROIDAL PHARMACEUTICAL PRODUCTS | ENDORECHERCHE, INC. (CA) | 2005-07-21 | — | — | WO | disclosed |
| US-6172091-B1 | METABOLIC CALCIUM IMBALANCE AND OSTEOPOROSIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000021910-A2 | 1,2-DISUBSTITUTED CYCLOPROPANES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-04-20 | — | — | WO | disclosed |
| US-4203898-A | ANTICARCINOGENIC | ELI LILLY AND COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4107165-A | ANTICOAGULANTS | ENDO LABORATORIES (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | NR1H2, NR1H3, NR1I2 | TAAR1 435/4885AOC3 4578/4885L3MBTL1 1226/4885 |
| US-20170320871-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESR1 | TAAR1 668/4885AOC3 3528/4885L3MBTL1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.